The world faces a serious scarcity of Covid-19 vaccines, and waiving mental property rights will not tackle the “most immediate problem,” says the worldwide CEO of an Indian pharmaceutical agency.
“I’m not so sure that an IP waiver at this stage is something that can … solve an immediate problem,” mentioned Umang Vohra of Cipla, who sees two points that have to be resolved.
The first and most fast drawback is the necessity to vaccinate hundreds of thousands, and the second is long-term entry to vaccines, he advised CNBC’s “Street Signs Asia” on Wednesday.
Waiving patent protections could also be useful with long-term entry, however is not going to probably assist a lot within the brief run, Vohra mentioned.
“We’re more about creating access at the immediate moment because I think that’s the need of the hour,” he mentioned.
“There should be more partnerships to be able to bring more vaccines into parts of the world that currently don’t have that supply,” he added.
Vials of the undiluted Pfizer-BioNTech vaccine for Covid-19, saved at -70 ° in a brilliant freezer.
Jean-Francois Monier | AFP | Getty Images
“I do believe that manufacturing for these is complicated, I do believe that there exists considerable know-how,” he mentioned. “It’s not just about IP, but it’s really about that technology and the experience that companies have had in formulating their technology.”
He added that giant vaccine producers seem like extra involved concerning the fragility of the availability chain quite than a capability scarcity.
Ultimately, Vohra mentioned waiving IP protections wouldn’t immediately present vaccines to elements of the world that do not have entry to the pictures — and that is the pressing drawback.
He mentioned present partnerships present a template for a way vaccines could be distributed.
“I think if we were to step back and solve for access, that’s a better goal to solve for, and that will allow many things to sort themselves out,” he mentioned.